Prof Philip Conaghan
SELECT COMPARE Risk benefit analysis
Clinical Summary Videos
View a summary of the SELECT COMPARE clinical trial - RINVOQ versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate.
View a summary of the SELECT MONOTHERAPY clinical trial - RINVOQ as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate.
View a summary of the SELECT NEXT clinical trial - Safety and efficacy of RINVOQ in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs.
View a summary of the SELECT BEYOND clinical trial - Safety and efficacy of RINVOQ in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs.
View a summary of the SELECT CHOICE clinical trial - Trial of upadacitinib or abatacept in rheumatoid arthritis.
You are now leaving the AbbVie Pro Portal and being re-directed to an external website which is not under the control of AbbVie. AbbVie is not responsible for content of any such site or any further links from such site.
Reporting of side effects (patients and public in the UK)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.
For medicines with black triangle: ▼ means the medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects.